Next Article in Journal
The Evanescent GacS Signal
Next Article in Special Issue
Effects of Different Drug Combinations in Immunodeficient Mice Infected with an Influenza A/H3N2 Virus
Previous Article in Journal
Intestinal Barrier Function in Health and Disease—Any Role of SARS-CoV-2?
Previous Article in Special Issue
TRIM Proteins and Their Roles in the Influenza Virus Life Cycle
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Microorganisms
Volume 8
Issue 11
10.3390/microorganisms8111745
microorganisms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

New Technologies for Influenza Vaccines

by
Steven Rockman
1,2,
Karen L. Laurie
1,*,
Simone Parkes
1,
Adam Wheatley
2 and
Ian G. Barr
2,3
1
Technical Development, Seqirus Ltd, Parkville, Victoria 3052, Australia
2
Department of Immunology and Microbiology, The University of Melbourne, Parkville, Victoria 3052, Australia
3
WHO Collaborating Centre for Reference and Research on Influenza, VIDRL, The Peter Doherty Institute for Infection and Immunity, Parkville, Victoria 3052, Australia
*
Author to whom correspondence should be addressed.
Microorganisms 2020, 8(11), 1745; https://doi.org/10.3390/microorganisms8111745
Submission received: 9 October 2020 / Revised: 4 November 2020 / Accepted: 4 November 2020 / Published: 6 November 2020
(This article belongs to the Special Issue The Biology of Influenza Viruses)
Browse Figure
Versions Notes

Abstract

Vaccine development has been hampered by the long lead times and the high cost required to reach the market. The 2020 pandemic, caused by a new coronavirus (SARS-CoV-2) that was first reported in late 2019, has seen unprecedented rapid activity to generate a vaccine, which belies the traditional vaccine development cycle. Critically, much of this progress has been leveraged off existing technologies, many of which had their beginnings in influenza vaccine development. This commentary outlines the most promising of the next generation of non-egg-based influenza vaccines including new manufacturing platforms, structure-based antigen design/computational biology, protein-based vaccines including recombinant technologies, nanoparticles, gene- and vector-based technologies, as well as an update on activities around a universal influenza vaccine.
Keywords: influenza; vaccine; universal vaccine; cell-culture; egg-based influenza vaccines; cell-based influenza vaccines; recombinant vaccines; mRNA vaccines influenza; vaccine; universal vaccine; cell-culture; egg-based influenza vaccines; cell-based influenza vaccines; recombinant vaccines; mRNA vaccines

Share and Cite

MDPI and ACS Style

Rockman, S.; Laurie, K.L.; Parkes, S.; Wheatley, A.; Barr, I.G. New Technologies for Influenza Vaccines. Microorganisms 2020, 8, 1745. https://doi.org/10.3390/microorganisms8111745

AMA Style

Rockman S, Laurie KL, Parkes S, Wheatley A, Barr IG. New Technologies for Influenza Vaccines. Microorganisms. 2020; 8(11):1745. https://doi.org/10.3390/microorganisms8111745

Chicago/Turabian Style

Rockman, Steven, Karen L. Laurie, Simone Parkes, Adam Wheatley, and Ian G. Barr. 2020. "New Technologies for Influenza Vaccines" Microorganisms 8, no. 11: 1745. https://doi.org/10.3390/microorganisms8111745

APA Style

Rockman, S., Laurie, K. L., Parkes, S., Wheatley, A., & Barr, I. G. (2020). New Technologies for Influenza Vaccines. Microorganisms, 8(11), 1745. https://doi.org/10.3390/microorganisms8111745

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop